Longevity Advantage
+5.10 yrs
vs US Gen Pop Baseline
Olympian Median Lifespan
82.60 yrs
50% Cohort Survival Age
US Baseline Median
77.50 yrs
CDC / SSA Actuarial Table
Survival to Age 85
48.2% vs 31.4%
+16.8% Relative Advantage
Kaplan-Meier Survival Fraction (100,000 Birth Cohort)
US Gen Pop
US Olympian Cohort
Longevity Delta
Age (Years: 20 to 105)
Gompertz Hazard: $\mu(x) = \alpha e^{\beta x}$ adjusted by covariate vector $\exp(\boldsymbol{\beta}^\top \mathbf{Z})$
Etiological Gain Decomposition Breakdown (+Years Added)
Sum: +5.10 Yrs
Epidemiological contribution to the overall net lifespan advantage calculated through multi-state life expectancy differential integration.
Actuarial Lifetable & Age-Specific Hazard Rates ($\mu_x$)
Decennial Milestones
| Age $x$ | US Pop $S(x)$ | Olympian $S(x)$ | Surv Gap | US Hazard $q_x$ | Oly Hazard $q_x$ | Hazard Ratio |
|---|
Epidemiological Context: Large retrospective cohort studies (e.g., Clarke et al., BMJ; Antero-Jacquemin et al.) confirm that elite Olympic athletes exhibit significantly lower all-cause mortality, primarily driven by a 30–45% reduction in cardiovascular disease mortality and lower cancer incidence, offset modestly in specific collision categories by late neurodegenerative and musculoskeletal complications.